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LETTERS TO THE EDITOR
The ri-PA Versus Streptokinase
Controversy-]
I should like to respond to two paint raised by Sherry aid Marder
in their recent editorial published by the Journal (I) .
I
. The editorial states that the Thrombalysis in Myocardial
Infarction Trial, Phase I (TIMI II was slopped short in dramatic
fashion in February 1985
. The National Hear . Lung, and Blood
Instants fNHLBII took (his action after a unanimous vote of all
Data and Safety Monitoring Board memhcrs who attended an
interim review of data in January 1985 . The Board recommended
stopping the trial lnouuase the prinaryquestinn defined in advance of
trial initiation, a comparison of reperfusiuu at 90 min in those
assigned to streplokinase versa, those assigned to recombinant
tissue-type plasminugen activator Irt-PAT . had been unequivocally
answered . To have continued randomiaalinn would have violated
the investigators' pact with prospective patients, that the question
was still open. Situations like this are the reason for establishing
Data and Safely Monitoring Boards to review interim data reports .
The TIMI I Board carried out its obligation of protecting patients
from unnecessary research risk and the NHLBI concurred with this
recommendation.
2. The TIMI 11 investigators elected to stadv the usefulness of
percutaneoas (ransluminal coronary angioplasty and beta-
adrenergie blocking agents as adjuncts to thrombolytic therapy in
TIMI 11 . The TIM1 11 protocol was mvlewed and approved by the
TIM] 11 Data and Safely Monitoring Board and the NHLBL Given
TIM[ I results and the virtual absence el studies assessing caronmy
angioplasty in patients with acute myocardial infarction at the lime
.
the TIMI 11 investigators chose the most important questions that
TIMI fl could address
. (he use of coronary angioplasty and bela-
blockers as adjuncts to thrombolytic therapy. A comparison of
carnival in patients assigned to rt-PA or streptokinase was clearly
beyond the sample si,e capacity of TIMI II .
The decisions to compare r(-PA and slreptokinase in TIMI 1 and
to assess coronary angioplasty and beta-blockers in TIM[ II were
arrived at in a free and open process involving many invcstigmors
and marry different 1 stitute advisory committees including the
NHLBI Advisory Council . Sherry and Marder (1) impugn the
motives of [his hard group of outstanding investigators and a tangy
number of valued NHLBI advisors
. The questions they raise are
imporu nt hot they can he answered satisfactorily by a simple
c%a„unaGuii ai the processes followed by the Institute . Their
editorial is unfounded and quite simply wrong in its interpretation of
the facts
. 11 uses information available today . the cast of rl-PA and
!he results nfG]SSl-212,31 and ISIS-3(4), tujudge decisions taken
in good forth more than 5 years ago in a branch of medical science
that has moved very rapidly.
Hindsight judgment is easy, but is it productive? I believe (he
lime has came (o focus on future development of improved therapies
and their espeditimis delivery to heart attack victims . The trials
supponed by the NHLBI plus those conducted by European inves-
tigators and others provide sufficient data for the scientific and
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practice communities to make sound therapeutic decisions for each
patient . This is what clinical trials are about.
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The rt-PA Versus Streptokinase
Controversy-. .1I
Every year or so Sherry and harder fire another broadside against
the TIMI trials, Let us examine each of the major criticisms leveled
by these edilolialists in their most recent exercise (1) .
Criticism 1
The prinrmy end point cf the trial. It is now clearihat thisend
point, the incidence of coronary artery reperfusion at
90 min after treatment induction, biased the results . Thus,
follow-up coronary angiography was performed 30 min
afterthe termination ofinfusion of streptokinase, al a lime
when the clot-dissolving activity of this agem was rapidly
diminishing and reclotting and rethrombosis could be
taking place
. In contras,lhe 90-min end point occurred at
the mid-poiol of a 1-h ri-PA infusion when rapid lysis was
continuing. Furthermore, early rethrombosis (within I h)
after the termination of n-PA therapy was known to be a
significant problem with rt-PA ., , . one that would negate
the potential benefits of early reperfusion in a give ..
patient . but it was not documented in this study because
follow-up angiugraphy was limited to the 90-min and
predischarge views- . . .
Also :
. . . the arbitrary 90-min end point
. . . would bypass the
short I1 14 past-treatment coronsty vessel status .
Response: Insofar as we can ascertain, no trial of thrombolytic
therapy has taken as many "looks" at coronary patency as did TIMI
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L. In addition to pretreatment angiograms, comparisons were made
at 10, 20, 30, 45, and 90 in xft, , the onset of therapy en well
as before hospital discharge
. Obviously only one of these "looks'
could he the prespeched primary end point. The 90-min end point
that was selected did, in fact, bias the results between the two
Ihrombolytic agents but
it did so
in f .nrof srreptokinase, not rt-PA .
because at 90 min 1000% of the dose of streptokinase but only 63% of
the total dose of rt-PA had been administered
. The circulating
half-life of streptokinase assured its continued activity 30 min after
the termination of the infusion . As was recognized and pointed out
in the initial preliminary report of TIM[ I, "An additional 30 mg of
rt-PA was administered after the 91)-urinate angiogram, and it is
possible that the patency rate (with rt-PA) might have been higher
after 180 minutes of infusion" (2).
In a subsequent more detailed report comparisons of coronary
reperfusian rates at other times between patients treated with
streptokinase and ri-PA were presented explicitly 11) as follows :
"The proportion of arteries (grades 0 or I at baseline) that
were successfully recanalized (grades 2 or 3) at 60 minutes after
the start of thromholytic therapy was 4010 1%] 130 in the rt-PA
and 23% 1271119) is the SK group (p <
.0011 and a1 30 min
after the start of thrombolytic therapy it was 2491 (27/113) in
the n-PA and 8th (91119) in the SK group (p ° .001 ; figure 4A) ."
'thus, the evidence of the superiority of n-PA over streptokinase
in achieving reperfusion at timer offer limn 90
"' "--r in
fact, documented and reported
. Elsewhere in this report the
TIMI investigators stated : ". . .Our observations at five time
intervals within the first hour of administration do not support
the suggestion that unequal duration of administration of the lyric
agents accounts for the superiority of rt-PA compared with SK"(31
.
A strong feature of Thdl I and insofar as we know a "first" in
lhrombolytic trials was the "triple bliodin¢' in which the coronary
arteriograms were interpreted by an invcsri8atnr in a Core Labora-
tory who bad no knowledge of The drug administered or tht clinical
situation .
In contrast to the editorialists' contention, the TIMI I investiga-
tors were also fully cognizant of the importance of patency rates at
times after the total dose of rt-PA had been administered but before
the peehospital discharge angiogram . They slated (3): "Patients
treated with ri-PA not only exhibited successful reperfusien mots
often at 90 min . but also maintained greater patency of the infarct-
related artery (by angiographic and clinical observation) at dis-
charge. . . . The incidence of clinical eeinfarction was similar in the
it-PA (13%) and the SK (12%) group . . . . The reocclosion rates
(estimated on the basis of angiography,
re-infarction,
and deatiii
were equal for rt-PA and SK, respectively"
(3). Again, contrary to
the assertion of Sherry and Marder 11)
. the TIMI I protocol specified
that angiography should be performed in all patients before hospital
discharge, not just those with open arteries at 90 min . Figure 5 in the
report (3) summarizes these results.
Amazingly, Sherry and Marder criticize the 90-min end point as
being 07th too car'
.y and too late! As we have indicated, several
earlier "looks" comparing the two tluombolytic agents yielded the
same results. The editorialists concede (I) that TIMI I was a
reperfusion trial that required pretreatment angiograms to identify
occluded vessels . To obtain a i-h post-n-PA treatment angiogram
(which they claim was "bypassed") to lock for reocclusion
would have necessitated keeping patients with Retire myocardial
infarction in the eathetenzatiun laboratory for >4 h for research
purposes, which is not acceptable practice
. However, the TIMI
investigators were eager to look at coronary artery patency at a
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time mtermediatc between 90 min amt hospital discharge . There .
Core . iii !he TOl 11 trial. arteriography, was performed 18 to 48 h
(average 32.5 ht after the onset of n-PA infusion m the 145% pa-
tients randomized to the invasive arm . Patcucy of the infarct-related
artery was observed in 84.6% (4); these data do not support Sherry
and Murder_ suggestion of excessive coronary reeechlsion after
n-PA, at least with the concomitant use of continuous intravenous
heparin .
Criticism 2
. . . because increasing clot age influenced lysis rates with
srtep!ekiaase but not with rt-PA the mean delay of 4.9 h
before treatment strongly favored the rt-PA group . . . .
Rmpmse. Again, this issue of thrombus age was addressed
explicitly in the T(41 I report and again the actual results do not
support the editorialists' criticism . The report (3) stales: "The
proportion of infarct-related arteries recaualized at each hourly
interval tram onset of symptoms to initiation of thramhelytic
therapy was always greater for patients receiving ri-PA than for
(hats diver SK al each interval within and beyond 4 hr . . . (table 3,
figure 4)." Subsequently, in a published letter to The editor of the
New Fngtand Jour at of hledicinz (5). in which the TIMI investi-
gators responded to one of Murder and Sherry's earlier criticisms
(6) . we staled : "The combined results lathe European Cooperative
Study Group Trial co
. aparing t-PA and SK (7) and of TIMI II for
potency rates showed that imravenens treatment with ri-PA appears
to be more effective than streptokitase treatment regardless of
whether it is administered within or after three hours." In fact, in
that letter we also reported that data pooled from the two trials
(TIMI I and the European trial) among patients treated within 3 h
showed patency tales of 81% fke rt-PA and 55% for srreptokinase
(p < 0 .01)
. h was Win pointed out that other investigators
bad Obtained similar disappointing results with streptokinase
:
"Even when SK is administered rapidly (1 .5 x 10s units Over 30
minutes) at a median of 3 his (a! wthin6hrs) after the msetof pain,
coronary arrerlogruphy performed a meditmof 4 .5 hrealtertheanset
of pain showed patency of the inform-related artery of only 44
percent" (81.
Criticism 3
The decision to drop streptokinase from further study proved
to be the greatest flaw in subsequent TIMI investigations .
for, instead ofa continuing
comparison
of physiologic and
clinical benefits of rt-PA and srreptokinase for other
agents), Phase II studies focused only on overcoming the
mayor weakness of rt-PA-its propensity for oeeecfu-
sion. . . .
Response. This criticism also is simply not based on fact . The
TIMI investigators concluded on the basis of Phase I that : 1) rt-PA
was about twice
as likely as streptokinase to open a closed infarct-
related artery within 90 min, the interval deemed necessary to
ensure optimal beneficial effects on the heart ; 2) no large differences
were noted for in-hospital clinical events
: and 3) the rate of
complications, particularly bleeding complications, was about the
same in both treatment groups
. On the basis of these findings the
TIMI investigators selected rt-PA as the better drug for further
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study. (The underlying premise for this decision was that lysis of
clot would prevent damage to heart muscle and thereby be of clinical
benefit .) In early 1985 the TIMI investigators began to design a
placebo-controlled trial intending to use rt-PA
. However, a number
of studies published or released in late 1985 required a reassessment
of this denigr . A meta-analysis (9) of multiple previously performed
studies that revealed substantial mortality reduction with the use of
Ihrmnbolvtic agents was published in the summer of 1985. In
addition, in 1985 a report (10) ofa trial conducted in the Netherlands
revealed mortally reduction in a group randomized to in traeoronary
and intravenous streplokinase compared with conventional therapy .
Finally. and moll tarpurtant, in October 1985 the results of the large
Italian trial (GISSr I) were released ; this study involved nearly
12,000 patients randomized to either intravenous streptokirnlsc or
conventional care and revealed substantial reduction in subsequent
munalily in those given streptokinase, particularly in those treated
within the I st h after the onset of symptoms (11) .
In the face of mounting evidence that thrombolylic therapy
reduced mortality the TIM[ investigators concluded that it would be
difficult and perhaps unethical to conduct a trial in which patients
were
enrolled into a placebo group within
4 h of the onset of
any-dial
infarction . Consideration was then given to two possible
studies, one of which vas a study of if-PA versus streplokinase with
mortality and morbidity as end points ; in essence, [his was a repeat
of TIMI I in a much larger number of patients anti with less invasive
testing. However, sample size estimates of the number of patients
needed to compare streptukinase and rt-PA for morality were
daunting. The number of patients subsequently nsed in GISSI 2
and ISIS 3 (20,000 to 411,0IJ0) wm clearly beyond the capacity of
TIMI if
.
The other potential study design considered was of adjuvant
therapy with percutaoeetts transluminal coronary angioplasty and
beta-blockers. In T'1Mi 1 it was noted, not surprisingly, that although
roperfusion was achieved in two thirds of patients treated with
n-PA, the infarcbrelated artery often showed residual narrowing ;
this, combined with reinfarctinn or reocclu sion, limited the potential
benefits from the thrombolylic agent- These findings led to consid-
eration of mechanical reeascularizatwn procedures such as coro-
nary, angioplasty as follow-up therapy to maintain the gain achieved
by thrombolylic therapy. On the basis of these and similar findings
in other thrombolytic trials, at the time TIMI Ii was being planned
a "reperfusion momentum" was sweeping the country . It was
widely believed that the optimal therapeutic strategy for acute
myocardial infarction was to administer a thrombolylic drug in a
coma unity hospital or emergency medical facility and immediately
transfer the patient (sometimes by helicopter) to a tertiary center for
coronary arteriographv and mechanical revascularization of the
infarct-related artery_ The TIMI investigators considered it to be of
importance to establish whether or not this course was dr-sir,ahle,
TIMI HA (12) and two other studies carried 0.1 almost simultu.
neously 113,14) showed that this strategy, which seemed so logical,
in fact lad deleterious effects
. Had early reacclusion with ri-PA
been as serious a problem as the editorialists contend, pmeney of the
infarct-related artery in TIMI II would not have been
81 .4% an
average of 1
.4h after the onset of ri-PA infusion (15) and 84,0% at
32 .8 h (41 and the immediately invasive strategy would probably
have been beneficial . The TIMI it investigators went further
and showed that even when carried out at an intermediate time
point (18 to 48 hli an invasive approach did not provide overall
honour (4) .
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The editorialists obviously do nut appreciate the importance of
or the widespread interest in the answers to the questions that TNT
If addressed . Comparisons of invasive and conservative strategies
were not limited tort-PA, These two strategies subsequently were
compared after sdmlnistmtion of intravenous anisoylated plnsmino-
gen streptokinase aclivator complex (APSAC) in the SWIFT trial
1101, which used a design almost identical to that or l'IMl II and
reached almost identical conclusions. The principal result in TIME
l1 -namely, that an invasive strategy aftar thrnrlbuiysis confers nn
benefit over a more conservative strategy-is now supported by a
mela-analysis (17) of eight large prospective randomized trials .
Slowing of the nnneccssary "reperfusion momentum" has reduced
the need for extensive new construction of entheterization facilities
and has saved the health care system many limes the costs of the
TIMI trials .
Other Criticisms
The editorialists quote selectively from TIMI I publications and
(hereby misrepresent the investigators positions . Any even-handed
analysis would have included the following two statements from
TIMI I : "The place for thtnmholutic therapy in the Cealment of
acute myocardial infarction depends on more Than 90 minute rece-
nalizalion rates" (2) and "The overall impact of rt-PA with respect
to myocardial salvage and reduction of mortality will probably be
greatest among patients who can be treated early and those
in v tiara
reocclusion and reinferction can be minimized" (3) .
The editorialists complain : "Indramaticfashion, the TIMI Phase
I trial was stopped short in February 1985 because of "substantial,
statistically significant differences in recanalizalion rates . . . ." The
responsibility of any Data and Safely Monitoring Committee
is
to
halt a trial when the question it basics has been answered unequiv-
ocally sod the TDAI I pats and Safety Committee did so when the
p value fur the comparison between the two thrombolylic agents
reached 0.001 in a trial that required pretreatment coronary aderi-
ography and -was eel without risk or discomfort.
The TIMI investigators' decision to assess coronary angioplasty
and beta-blockers as adjuncts to tt-PA in patients with acute
infarction was taken in late 1985. It might be useful to recall that
al that time n-PA was not available (it was approved by the Food
and Drug Administration in 1987), the, price
of rt-PA had not
been established and the price disparity between n-FA and strep-
tekinase was unknown . This is yet another example of Monday
morning quarterbacking by the editorialists . Also, it was surprising
to learn from them that the Thrombolysis and Angoplasty in
.Myocardial Infarction (TAMI) investigators include Johns . Gold,
Leinbaeh and the Massachusetts General Hospital group (see their
reference 29)!
Interestingly. the editorial by Monrad (ll), which immediately
precedes Sherry and Mard^'s editorial in the Journal of the
Amrrirnn Coffee,
of
Cardiology (1),
criticizes the New
EnRlond
Jwrrnol
oj
.Nedtcine for "failing in its journalistic responsibility in
the selection of editorial comment	Monad concludes by
proposing "that standards of review and editorial comment mandate
critical distance and independence." In this last respect we agree
with Monrad and only wish that the very journal in which he
proposed these standards had adhered to them in its
I en, near
article!
In nn-y, the editorial by Sherry and Marder . like their
previous criticisms of TIM[, is distorted, "rewrites history" and in
several instances frankly inverts the facts
. Sadly, as it this were not
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enough, they have hecome more strident anti now impugn, by
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The rl-PA Versus Streptoktnase
Controversy-III
T,c preceding letter by Breunwald et al, is designed to neppte the
.c
.urah and vmpottance of the (hones of our cditerel
. The ltiler
was based on the undeserved popalaeiy given to the results of the
II st I /Mt trial . a trial Pawed in several respects and in which the
value of 9p-min potency rates, as determined in that study, was
misirierpretud i
I1
. This fed fu deci eons and a sales of ptbt ieolinns
and prc sr•n
lations that had an enormous influence on the cardiology
community and promoted the use of a very expensive dnnmbolytic
agent those superictils, over other agars in safety . myocardial
salvage, mortality reduction and cost effectiveness has never been
established . The volt has been an unwarranted asperse to the
health care system fur the treatment of acute
my-dial
infarction.
The attiutde of the authors of the letter. who continue to defaml
their position despite the avertshehning information about the lack
of superiority of n-PA over other agents in terms of
a costRreneft!
dik ratio
is
4WRcult to finders trot! oT
m wstifv
. Furthermore their
resistance to appreciating why the results with tt-PA in TIMI Phase
I shmdd not have been interpreted ac representing a remarkable
advance in thrunlbolvtic therapy for acute myocardial tether Lion it
surprising since we have altempled in a series of publications
(2-8)
.
beginning as far back as 1985
. to provide an objective evaluation of
rt-PA and otter thmmholytie agents in the management of acute
myocardial infarction .
In answer to Lenfant's companion letter, it should be noted that
the N HLBI as an authority figure and a public institution needs to be
very cautious in its position relative to a specific agent . The latter
comment refers to the continued use of funds in large amounts to
support trials With rt-PA . a s in the various TIM( studies, in the
absents of any evidence of superiority in safety . myocardial salvage
or mortality reduction (including the lack of any clinical benefit in
the original TIM( Phase I study) over other thmmbolytic agents
.
As for the "valued NHLBI
advisors,"
it should be noted that
this group
. which included some advisors who favored an in-depth
analysis hetore proceeding with TIM[ If or who disagreed with
decisions regarding the organization of future trials . was dropped
under a reorganizaliun plan .
We agree that there is a need now `to focus on future develop-
meals of improved therapies and their expeditious delivery to heart
a:iack victims;' hot this has 'Jean long overdue.
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